Yang Yang, Feng Qi, Luan Ying, Liu Hui, Jiao Yuxue, Hao Huijie, Yu Bo, Luan Yi, Ren Kaidi
Clinical Systems Biology Research Laboratories, Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2023 Aug 11;14:1229297. doi: 10.3389/fphar.2023.1229297. eCollection 2023.
Copper (Cu) is a vital trace element for maintaining human health. Current evidence suggests that genes responsible for regulating copper influx and detoxification help preserve its homeostasis. Adequate Cu levels sustain normal cardiac and blood vessel activity by maintaining mitochondrial function. Cuproptosis, unlike other forms of cell death, is characterized by alterations in mitochondrial enzymes. Therapeutics targeting cuproptosis in cardiovascular diseases (CVDs) mainly include copper chelators, inhibitors of copper chaperone proteins, and copper ionophores. In this review, we expound on the primary mechanisms, critical proteins, and signaling pathways involved in cuproptosis, along with its impact on CVDs and the role it plays in different types of cells. Additionally, we explored the influence of key regulatory proteins and signaling pathways associated with cuproptosis on CVDs and determined whether intervening in copper metabolism and cuproptosis can enhance the outcomes of CVDs. The insights from this review provide a fresh perspective on the pathogenesis of CVDs and new targets for intervention in these diseases.
铜（Cu）是维持人体健康的重要微量元素。目前的证据表明，负责调节铜流入和解毒的基因有助于维持其体内平衡。充足的铜水平通过维持线粒体功能来维持正常的心脏和血管活动。与其他形式的细胞死亡不同，铜死亡的特征是线粒体酶的改变。针对心血管疾病（CVD）中铜死亡的治疗方法主要包括铜螯合剂、铜伴侣蛋白抑制剂和铜离子载体。在这篇综述中，我们阐述了铜死亡涉及的主要机制、关键蛋白和信号通路，以及它对心血管疾病的影响和在不同类型细胞中所起的作用。此外，我们探讨了与铜死亡相关的关键调节蛋白和信号通路对心血管疾病的影响，并确定干预铜代谢和铜死亡是否可以改善心血管疾病的预后。这篇综述的见解为心血管疾病的发病机制提供了新的视角，并为这些疾病的干预提供了新的靶点。
